Premium
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)
Author(s) -
Herold M.,
Hoster E.,
Janssens A.,
McCarthy H.,
Tedeschi A.,
Pocock C.,
Rosta A.,
Schmidt P.,
Trněný M.,
Burciu A.,
FingerleRowson G.,
Rufibach K.,
Zeuner H.,
Hiddemann W.,
Marcus R.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_136
Subject(s) - medicine , obinutuzumab , rituximab , bendamustine , gastroenterology , interim analysis , neutropenia , clinical endpoint , surgery , febrile neutropenia , chemotherapy regimen , chemotherapy , lymphoma , clinical trial